All Psoriasis (PsO) articles
-
ArticleInside Zasocitinib: a new model for TYK2 inhibition in immune-mediated diseases
Zasocitinib is a highly selective, investigational TYK2 inhibitor developed to target immune-mediated diseases with fewer off-target effects than traditional JAK inhibitors. This article explores its mechanism, selectivity data and clinical progress.